The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2019 | Rituximab maintenance shows no advantage over observation in DLBCL
Pieternella Lugtenburg, MD, PhD, Erasmus University Medical Center, Rotterdam, Netherlands, discusses the results from a randomized Phase III study of rixtuximab maintenance for patients with diffuse large B-cell lymphoma (DLBCL) in first complete remission (HOVON 84 NHL; NTR1014). For this study population, maintenance therapy with rituximab displayed no advantage compared with observation alone. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.
